MDDCX
Price
$33.07
Change
+$0.68 (+2.10%)
Updated
Jul 31 closing price
Net Assets
1.94B
VEMAX
Price
$48.64
Change
+$0.61 (+1.27%)
Updated
Jul 31 closing price
Net Assets
163.32B
Interact to see
Advertisement

MDDCX vs VEMAX

MDDCX vs VEMAX Comparison Chart in %
View a ticker or compare two or three
VS
MDDCX vs. VEMAX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDDCX is a Buy and VEMAX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VEMAX has more cash in the bank: 163B vs. MDDCX (1.94B). MDDCX pays higher dividends than VEMAX: MDDCX (6.63) vs VEMAX (2.32). MDDCX was incepted earlier than VEMAX: MDDCX (32 years) vs VEMAX (20 years). MDDCX (1.37) is less costly to investors than VEMAX (0.13). MDDCX is a more actively managed with annual turnover of: 88.00 vs. VEMAX (6.00). MDDCX has a lower initial minimum investment than VEMAX: MDDCX (1000) vs VEMAX (3000). MDDCX annual gain was more profitable for investors over the last year : 42.22 vs. VEMAX (19.34). VEMAX return over 5 years is better than : 27.49 vs. MDDCX (22.44).
MDDCXVEMAXMDDCX / VEMAX
Total Expense Ratio1.120.13862%
Annual Report Gross Expense Ratio1.370.131,054%
Fund Existence32 years20 years-
Gain YTD20.8509.106229%
Front Load5%N/A-
Min. Initial Investment1000300033%
Min. Initial Investment IRA100N/A-
Net Assets1.94B163B1%
Annual Yield % from dividends6.632.32286%
Returns for 1 year42.2219.34218%
Returns for 3 years54.4146.41117%
Returns for 5 years22.4427.4982%
Returns for 10 years127.3489.08143%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MDFGX30.490.46
+1.53%
BlackRock Capital Appreciation Inv A
OIEQX28.620.24
+0.85%
JPMorgan Equity Income R4
GTLOX23.840.06
+0.25%
Glenmede Disciplined US Eq Ptf
CSDGX17.130.04
+0.23%
Copeland SMID Cap Dividend Growth A
GTMUX24.78-0.03
-0.12%
Goldman Sachs Small/Mid Cap Growth R6